Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 19, 2010 Brian Orelli	The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology.
The Motley Fool September 29, 2010 Brian Orelli	Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals.
The Motley Fool August 31, 2007 Brian Orelli	A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending.
The Motley Fool January 4, 2005 W.D. Crotty	A StemCell First News of an FDA application sends StemCells' stock soaring.
The Motley Fool May 2, 2011 Brian Orelli	StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies.
The Motley Fool November 15, 2011 Brian Orelli	When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells.
The Motley Fool July 26, 2004 Brian Gorman	Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble.
The Motley Fool November 9, 2004 Charly Travers	Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works.
The Motley Fool August 2, 2010 Brian Orelli	Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today.
The Motley Fool August 27, 2007 Brian Orelli	Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note.
The Motley Fool September 20, 2005 Rich Smith	ViaCell's Cancer Trial Snag The cord blood collector suffers a research setback. Investors should keep in mind that the real money-maker behind ViaCell is its ViaCord cord blood storage business.
BusinessWeek June 27, 2005 Arlene Weintraub	Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood.
The Motley Fool January 31, 2011 Brian Orelli	Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet.
The Motley Fool May 3, 2005 Charly Travers	Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not.
The Motley Fool May 26, 2009 Brian Orelli	A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents.
The Motley Fool November 8, 2005 Rich Smith	ViaCell Looks Healthier The cord blood collector reports narrowing losses. Investors, take note.
The Motley Fool November 30, 2004 Rich Smith	Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year.
Pharmaceutical Executive October 1, 2012 Ben Comer	Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures.
The Motley Fool October 12, 2010 Travis Hoium	Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial.
The Motley Fool December 22, 2009 Brian Orelli	Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year
Bio-IT World Dec 2005/Jan 2006 Maureen McDonough	The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line.
The Motley Fool February 23, 2007 Rich Smith	Foolish Forecast: ViaCell Doing Well? The cord blood specialist is set to report its fourth-quarter and full-year 2006 numbers shortly. Investors, here is what you can expect to see.
The Motley Fool November 28, 2007 Brian Orelli	Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells.
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
BusinessWeek May 24, 2004 Arlene Weintraub	Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market
The Motley Fool December 1, 2008 Brian Orelli	Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now.
Chemistry World February 23, 2015 Phillip Broadwith	Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission.
Fast Company March 2009 Tim McKeough	Banking Stem Cells For Future Use A personal banking system for stem cells.
The Motley Fool December 23, 2011 Brian Orelli	Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins.
The Motley Fool April 14, 2008 Brian Orelli	Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost.
HHMI Bulletin May 2010 Sarah C.P. Williams	Young Again Niche cells can reverse the aging of stem cells.
BusinessWeek September 23, 2010 Rob Waters	Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed.
Scientific American January 17, 2007 Charles Q. Choi	A Stroke for Stem Cells The brain becomes a target in stem cell clinical trials.
BusinessWeek June 13, 2005 Arlene Weintraub	A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage.
The Motley Fool May 4, 2006 Rich Smith	ViaCell Looking Sickly As expected, the company remains solvent by virtue of one division: its ViaCord umbilical cord blood storage unit, which provided $11.9 million of the quarter's $12.1 million in revenues. But even that good news fails to outweigh the bad news. Investors, take note.
Salon.com July 17, 2000 Alix Christie	The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it.
The Motley Fool February 2, 2005 Rich Duprey	Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Reason October 2001 Ronald Bailey	Blastocyst Brouhaha Which human cells count as people?
The Motley Fool July 14, 2011 Rich Smith	What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer.
The Motley Fool October 14, 2005 Tim Beyers	Baby Breaker Birth Announcements We track the week in private equity in search of investments of the future. Virxsys... Raven Biotechnologies...
The Motley Fool November 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron.
The Motley Fool October 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.
Chemistry World February 4, 2011 Harriet Brewerton	Transplant tracking Magnetic nanoparticles could be used to track neural stem cells after a transplant in order to monitor how the cells heal spinal injuries, say UK scientists.
The Motley Fool April 27, 2007 Rich Smith	Foolish Forecast: ViaCell Doing Swell? The cord blood specialist is set to release its first-quarter 2007 earnings. Investors, here is what you can expect to see.
The Motley Fool March 2, 2005 Rich Smith	ViaCell Under the Microscope Cord blood collector makes its first earnings announcement tomorrow. Investors will likely be shining harsh lights on the company's financial statements.
Chemistry World December 8, 2015 Liisa Niitsoo	A sound idea for treating lung disease Scientists in Australia have made a portable device that gently vibrates stem cells with sound waves to turn them into an aerosol. The system could be an effective route for treating various pulmonary diseases.
HHMI Bulletin May 2011 Jim Schnabel	Oxygen on the Brain An ancient cellular program to protect cells when oxygen is low seems crucial for the production of new brain cells.
BusinessWeek July 26, 2004 Arlene Weintraub	The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed.
The Motley Fool October 2, 2007 Brian Orelli	PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies.